CytomX Therapeutics, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck for CytomX's first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -2.86% | -2.86% | +9.68% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
125.5 USD | +0.81% | -3.05% | 318B | ||
1.7 USD | -2.86% | -2.86% | 132M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.68% | 132M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)